SWTX vs. IOVA, DNLI, IMCR, TWST, ACLX, VCEL, RXRX, APGE, KYMR, and ADMA
Should you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Immunocore (IMCR), Twist Bioscience (TWST), Arcellx (ACLX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
SpringWorks Therapeutics (NASDAQ:SWTX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation.
In the previous week, SpringWorks Therapeutics had 2 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 6 mentions for SpringWorks Therapeutics and 4 mentions for Iovance Biotherapeutics. SpringWorks Therapeutics' average media sentiment score of 0.69 beat Iovance Biotherapeutics' score of 0.28 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
SpringWorks Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
SpringWorks Therapeutics currently has a consensus price target of $68.83, suggesting a potential upside of 63.89%. Iovance Biotherapeutics has a consensus price target of $24.64, suggesting a potential upside of 129.18%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than SpringWorks Therapeutics.
SpringWorks Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Iovance Biotherapeutics received 468 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. Likewise, 74.50% of users gave Iovance Biotherapeutics an outperform vote while only 68.18% of users gave SpringWorks Therapeutics an outperform vote.
77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.6% of SpringWorks Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
SpringWorks Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -23,615.70%. SpringWorks Therapeutics' return on equity of -66.48% beat Iovance Biotherapeutics' return on equity.
Summary
Iovance Biotherapeutics beats SpringWorks Therapeutics on 10 of the 17 factors compared between the two stocks.
Get SpringWorks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SpringWorks Therapeutics Competitors List
Related Companies and Tools
